Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Subscribe To Our Newsletter & Stay Updated
